Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Burning Rock Biotech (BNR) Cost of Revenue (2020 - 2025)

Historic Cost of Revenue for Burning Rock Biotech (BNR) over the last 6 years, with Q3 2025 value amounting to $4.6 million.

  • Burning Rock Biotech's Cost of Revenue fell 1218.77% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.2 million, marking a year-over-year decrease of 967.19%. This contributed to the annual value of $26.2 million for FY2024, which is 2503.65% down from last year.
  • According to the latest figures from Q3 2025, Burning Rock Biotech's Cost of Revenue is $4.6 million, which was down 1218.77% from $5.6 million recorded in Q2 2025.
  • In the past 5 years, Burning Rock Biotech's Cost of Revenue registered a high of $7.6 million during Q1 2022, and its lowest value of $4.5 million during Q1 2021.
  • Over the past 5 years, Burning Rock Biotech's median Cost of Revenue value was $5.7 million (recorded in 2023), while the average stood at $5.8 million.
  • Its Cost of Revenue has fluctuated over the past 5 years, first soared by 6695.36% in 2022, then tumbled by 1715.14% in 2024.
  • Over the past 5 years, Burning Rock Biotech's Cost of Revenue (Quarter) stood at $6.6 million in 2021, then fell by 9.79% to $5.9 million in 2022, then rose by 1.89% to $6.1 million in 2023, then dropped by 17.15% to $5.0 million in 2024, then fell by 8.18% to $4.6 million in 2025.
  • Its Cost of Revenue was $4.6 million in Q3 2025, compared to $5.6 million in Q2 2025 and $4.9 million in Q1 2025.